Antibody Drug Conjugates: The Patent Landscape for a New Class of Cancer Treatment
Aug 7th, 2018 by Steve Kennedy | Biotech/Pharma | Recent News & Articles |
Over the last decade, antibody-drug conjugates (ADCs) have emerged as a highly promising new class of biopharmaceuticals. By taking advantage of the specificity of monoclonal antibodies and the potency of small-molecule chemotherapy drugs, ADCs have proven to provide a highly effective combination – particularly in the oncology space,. The recent […]
